What We're Reading: Page 244
Industry reads hand-picked by our editors
Sep 07, 2018
-
Financial Times
Opioid billionaire granted patent for addiction treatment
-
TechCrunch
23andMe underscores that privacy-loving customers need to opt out of its data deal with GlaxoSmithKline
-
Forbes
Will Trump's pharma shaming bring down drug prices? Not likely, poll says
-
Boston Business Journal
Biotech VCs debate AI, globalization during Boston panel
Sep 06, 2018
-
The Wall Street Journal
Blood-testing firm Theranos to dissolve
-
Scientific American
GMOs are not agriculture's future — biotech is
-
Boston Business Journal
Histogenics to seek FDA approval for cell therapy despite failed study
-
Business Insider
A startup with ties to Bayer has inked a $122 million deal to make lab-grown marijuana — and it's eyeing the pharma industry
-
The Moran Company
PhRMA, hospital war over drug prices heats up
Sep 05, 2018
-
The Wall Street Journal
Big Pharma Catches Up With Biotech
-
Evening Standard
Pfizer says getting ready for Brexit will cost $100M
-
Xconomy
Westlake Bio unveils $320M fund to put Los Angeles on the biotech map
-
The New York Times
Scientists are retooling bacteria to cure disease
Sep 04, 2018
Aug 31, 2018
Aug 30, 2018
-
Science
The Alzheimer’s gamble: NIH tries to turn billions in new funding into treatment for deadly brain disease
-
Reuters
Europe ready to cash in on cheap copies of AbbVie biotech drug
-
Bloomberg
Hedge funds' shift to health care may be a hedge too far
-
The Washington Post
FDA pushes for development of non-opioid pain medications
Aug 29, 2018
-
The Wall Street Journal
Biotech Analysts Receive Lucrative Paydays From Industry Boom
-
Politico
Did Patrick Soon-Shiong's high-tech gamble help bring 6 hospitals to the brink?
-
Bloomberg
Wall Street expats angle for piece of China’s biotech drug boom
-
The Boston Globe
Will 2018 set a record for biotech IPOs?
Previous
